文献速递妇科

尼拉帕利维持治疗中国铂敏感复发性卵巢癌患者的成本-效果分析

Cost-effectiveness analysis of niraparib maintenance therapy in Chinese patients with platinum-sensitive recurrent ovarian cancer.
PubMed 文献 · Gynecol Oncol · 2023-05-18

本研究采用三状态分区生存模型,评估尼拉帕利对比常规监测作为中国铂敏感复发性卵巢癌维持治疗的成本-效果。模型采用终身时间范围、4周周期,疗效数据来自NORA研究,成本和效用数据来自已发表研究和在线数据库,成本和健康结局按年贴现率5%贴现。基础分析显示尼拉帕利不具有成本-效果,ICER为42,888美元/QALY,对比2022年中国GDP人均1至3倍的支付意愿阈值(12,741至38,233美元/QALY)。敏感性分析显示ICER对安慰剂组后续治疗成本最敏感,概率敏感性分析显示在支付意愿阈值下尼拉帕利具有成本-效果的概率为2.9%至50.1%。结论认为尼拉帕利改善生存获益但成本-效果较低,根据患者实际情况合理减量或降低尼拉帕利价格可提高其成本-效果。

要点

  • 尼拉帕利维持治疗铂敏感复发性卵巢癌的ICER为42,888美元/QALY,高于2022年中国GDP人均1至3倍的支付意愿阈值(12,741至38,233美元/QALY)。
  • 概率敏感性分析显示,在支付意愿阈值下尼拉帕利具有成本-效果的概率为2.9%至50.1%。
  • 单因素确定性敏感性分析显示ICER对安慰剂组后续治疗成本最敏感。

核心结论

  • 尼拉帕利改善铂敏感复发性卵巢癌患者的生存获益,但在支付意愿阈值下相比常规监测成本-效果较低,因其成本更高。
  • 根据患者实际情况合理减量或降低尼拉帕利价格可提高其成本-效果。

研究设计与样本

  • 本研究采用三状态分区生存模型,采用终身时间范围,周期长度为4周。
  • 疗效数据来自NORA研究,成本和效用数据来自已发表研究和在线数据库,成本和健康结局按年贴现率5%贴现。
  • 主要结局包括质量调整生命年(QALY)和增量成本-效果比(ICER)。
  • 支付意愿阈值设为2022年中国GDP人均的1至3倍(12,741至38,233美元/QALY)。
  • 进行了敏感性分析以验证模型结果的稳健性。

主要发现

  • 基础分析中,尼拉帕利相比常规监测的ICER为42,888美元/QALY,在支付意愿阈值下不具有成本-效果。
  • 单因素确定性敏感性分析表明,ICER值对安慰剂组后续治疗成本最敏感。
  • 概率敏感性分析表明,在支付意愿阈值下,尼拉帕利具有成本-效果的概率为2.9%至50.1%。

关键数值与推荐

  • 支付意愿阈值设为2022年中国GDP人均的1至3倍,即12,741至38,233美元/QALY。
  • 基础分析中尼拉帕利对比常规监测的ICER为42,888美元/QALY。
  • 概率敏感性分析中,在支付意愿阈值下尼拉帕利具有成本-效果的概率范围为2.9%至50.1%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: This study aimed to evaluate the cost-effectiveness of niraparib versus routine surveillance as maintenance therapy for patients with platinum-sensitive recurrent ovarian cancer in China. METHOD: A three-state partitioned survival model that adopted a lifetime horizon with a 4-week cycle length was developed. Efficacy data were derived from the NORA study. Cost and utility data were obtained from published studies and online databases. The cost and health outcomes were discounted at an annual rate of 5%. In this analysis, the primary outcomes included quality-adjusted life-year (QALY) and incremental cost-effectiveness ratio (ICER). The willingness-to-pay (WTP) thresholds were set at 1 to 3 times the gross domestic product per capita of China in 2022 ($12,741 to $38,233/QALY). Sensitivity analyses were conducted to verify the robustness of the model results. RESULTS: In the base-case analysis, niraparib was not found to be cost-effective, with an ICER of $42,888/QALY compared with routine surveillance at the WTP thresholds. One-way deterministic sensitivity analyses indicated that the ICER value was most sensitive to the cost of subsequent treatment in placebo group. The probabilistic sensitivity analysis suggested that at the WTP thresholds, the probability of niraparib being cost-effective was 2.9% to 50.1%. CONCLUSIONS: Niraparib improves the survival benefit of platinum-sensitive recurrent ovarian cancer patients. However, it seems to be less cost-effective, as it has higher costs than routine surveillance at the WTP thresholds. Reasonable dose reduction according to the patient's actual situation or lowering the price of niraparib can improve its cost-effectiveness.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Qiu Y, Zha J, Ma A, et al. Cost-effectiveness analysis of niraparib maintenance therapy in Chinese patients with platinum-sensitive recurrent ovarian cancer. Gynecol Oncol. 2023. PMID: 37209503. doi:10.1016/j.ygyno.2023.05.010

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。